A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
Study Details
Study Description
Brief Summary
This study seeks to correlate microbial sequencing data from a punch biopsy in patients with skin cancer both melanoma and non-melanoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The human Skin microbiome is a complex, interconnected web of microbes, living in a symbiotic relationship with their host. There are greater than ten times more bacteria on our bodies than there are human cells, all in a delicate and ever-changing balance to maintain a healthy skin microbiome. When this balance is disrupted, a condition known as dysbiosis, disease can occur. There is still a debate over whether dysbiosis is a cause of disease or a symptom of it. Naturally, since the microbiome has such a profound impact on human health, we want to study and learn as much about the microbiome as possible. By correlating this data with medical records for the patient's skin cancer, connections may begin to be drawn between organisms present in the microbiome of the skin microbiome, and skin cancer. Much like fingerprints, no microbiome is identical therefore the only chance we have at understanding disease is by looking at the skin microbiome and comparing the microorganisms on a patient with skin cancer biopsy and non-skin cancer biopsy.
Study Design
Outcome Measures
Primary Outcome Measures
- Correlation of Skin Microbiome to Cancer via Relative Abundance Found in Microbiome Sequencing [1 year]
Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the skin microbiome in both cancerous and non-cancerous areas. These data will then be compared to elucidate unique qualities of the microbiome in skin cancer.
Secondary Outcome Measures
- Validation of sequencing methods [1 year]
To validate the sequencing methods used to generate microbiome data
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed informed consent
-
18 years of age or older
-
Diagnosis of skin cancer, both melanoma and non-melanoma
-
Able/willing to have a skin punch biopsy in a non-cancerous location
Exclusion Criteria:
-
Unable/unwilling to sign informed consent
-
Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | ProgenaBiome | Ventura | California | United States | 93003 |
Sponsors and Collaborators
- ProgenaBiome
Investigators
- Principal Investigator: Sabine Hazan, MD, ProgenaBiome
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ProgenaBiome-003